Literature DB >> 22203927

VEGF and his R1 and R2 receptors expression in mast cells of oral squamous cells carcinomas and their involvement in tumoral angiogenesis.

Raluca Ciurea1, Cl Mărgăritescu, Cristiana Simionescu, A Stepan, M Ciurea.   

Abstract

More than 90% of malignant neoplasms of the oral cavity are squamous carcinomas of oral mucosa and most are conventional type. This study included 60 cases of oral squamous carcinoma processed by usual histological technique and stained with Hematoxylin-Eosin and Alcian Blue-Safranin (Alcian Blue powder from Sigma Aldrich, code A5268-25G) and diagnosed in the Department of Pathology, University of Medicine and Pharmacy of Craiova. Double immunohistochemical (CD105-tryptase, VEGF-, VEGFR1-, VEGFR2-tryptase) or combined histochemical and immunohistochemical reactions (VEGF÷ VEGFR1÷ VEGFR2÷Alcian Blue-Safranin) followed the particular morphological aspects of the mast cells, their relation with the blood vessels and the overlap signal of tryptase and Alcian Blue-Safranin÷VEGF and its R1 and R2 receptors in mast cells. Immunostaining for VEGF and its R1 and R2 receptors was present both in tumor cells and mast cells. Double immunohistochemical-histochemical reactions allowed us angiogenic profiling the mast cells. The signal overlap was present for VEGF-, VEGFR1-, VEGFR2-tryptase intratumoral and tumor invasion front mast cells. Student's t-test for comparison of intratumoral and the invasion front MDM showed highly significant value (p=3.23 E-08). VEGF÷ VEGFR1÷ VEGFR2÷Alcian Blue-Safranin revealed particular morphological aspects of mast cells, in with different morphology, shapes, sizes and degrees of degranulation. Statistical analysis showed a linear correlation between MDM and MVD inside the tumor (Pearson coefficient =0.47) and a weak linear correlation at the front of invasion (Pearson coefficient =0.19). This study has highlighted the importance of mast cells in the tumor growth of the oral squamous carcinomas, especially in terms of their proangiogenic profile (expression of VEGF and its R1 and R2 receptors). In addition, their quantification as MDM makes this parameter a useful prognostic marker.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22203927

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  6 in total

1.  VEGFR1 and VEGFR2 in lip carcinogenesis and its association with microvessel density.

Authors:  Carla Ariotti; Vivian Petersen Wagner; Gabriela Salvadori; Vinicius Coelho Carrard; Marco Antônio Trevizani Martins; Joao Julio da Cunha Filho; Luise Meurer; Manoela Domingues Martins
Journal:  Tumour Biol       Date:  2015-04-21

2.  Mast cell marker gene signature in head and neck squamous cell carcinoma.

Authors:  Zhimou Cai; Bingjie Tang; Lin Chen; Wenbin Lei
Journal:  BMC Cancer       Date:  2022-05-24       Impact factor: 4.638

Review 3.  Targeting mast cells in gastric cancer with special reference to bone metastases.

Authors:  Christian Leporini; Michele Ammendola; Ilaria Marech; Giuseppe Sammarco; Rosario Sacco; Cosmo Damiano Gadaleta; Caroline Oakley; Emilio Russo; Giovambattista De Sarro; Girolamo Ranieri
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

4.  Mast cells and angiogenesis in malignant and premalignant oral lesions: An immunohistochemical study.

Authors:  Daisy Laishram; Kavita Rao; H S Uma Devi; N S Priya; T Smitha; H S Sheethal
Journal:  J Oral Maxillofac Pathol       Date:  2017 May-Aug

5.  Expressions of vascular endothelial growth factor receptors, Flk1 and Flt1, in rat skin mast cells during development.

Authors:  Miki Koh; Syunya Noguchi; Mami Araki; Hirotada Otsuka; Makoto Yokosuka; Satoshi Soeta
Journal:  J Vet Med Sci       Date:  2020-04-22       Impact factor: 1.267

Review 6.  The role of mast cells in oral squamous cell carcinoma.

Authors:  Swetha Gudiseva; Arvind Babu Rajendra Santosh; Raviteja Chitturi; Vamsikrishna Anumula; Chandrashekar Poosarla; Venkat Ramana Reddy Baddam
Journal:  Contemp Oncol (Pozn)       Date:  2017-03-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.